This is a type of protein called a growth factor. It helps skin cells, called keratinocytes, grow and divide. It's sometimes used in medicine to help skin heal after certain treatments.
Every report comes from a Lived member, sent anonymously.
Have you tried Fibroblast Growth Factor 7 for Stomatitis?
Fibroblast growth factor 7, also called keratinocyte growth factor (KGF), is a natural protein that helps repair the linings of the mouth, gut and other body surfaces. A lab-made version, palifermin (brand name Kepivance), is a prescription medicine used to reduce severe oral mucositis: painful inflammation and sores of the mouth lining caused by intensive cancer treatment. Palifermin is approved for people with blood cancers, such as lymphoma, leukemia or multiple myeloma, who receive very high-dose treatment followed by an autologous stem cell transplant (a transplant of their own previously collected stem cells). It is meant for treatment plans expected to cause severe mouth sores in most people. An international guideline from the Multinational Association of Supportive Care in Cancer and the International Society of Oral Oncology recommends it when the conditioning treatment includes both high-dose chemotherapy and total body irradiation. Its benefit is limited to that setting. Palifermin did not reduce severe mouth sores in people receiving stem cells from a donor (an allogeneic transplant), and it did not help with high-dose melphalan, a chemotherapy regimen often used before transplant for multiple myeloma. It is not a treatment for cancer itself, and its safety and effectiveness have not been established in people with cancers that are not blood cancers, such as skin or head and neck cancers.
Chemotherapy and radiation damage cells that divide quickly, including the cells lining the mouth and throat. When that lining breaks down, ulcers form, eating and swallowing become painful, and the open sores can let infection in. The body normally makes more keratinocyte growth factor after this kind of injury. The protein attaches to a receptor on epithelial cells (the cells that form the skin and the body's inner linings) and prompts them to multiply, mature and move in to cover damaged areas. Palifermin is a slightly shortened version of this protein, made in bacteria, with part of the chain removed to make it more stable. Giving it before high-dose treatment builds up the mouth lining so it better withstands the damage; in animal studies it thickened the lining of the tongue and cheeks. Doses after the transplant support recovery. Blood-forming cells do not carry the KGF receptor, so palifermin is not expected to act on the bone marrow, and in trials it did not delay the recovery of blood counts after transplant.
Palifermin is given only by the transplant or oncology team, as a quick injection into a vein (an IV bolus), usually through the IV line already in place for transplant. The usual course is six doses, with the amount based on body weight: one dose a day for three days before the high-dose treatment begins, and one dose a day for three days afterward, starting on the day of the stem cell infusion once the infusion is finished. Timing is the main safety point. Palifermin is not given within 24 hours before, during, or within 24 hours after the high-dose chemotherapy. In one trial, giving it too close to chemotherapy made mouth sores more severe and longer-lasting; the study's safety committee attributed this to the stimulated lining cells dividing rapidly at the moment the chemotherapy hit, which made them more sensitive to it. Because the schedule is built around the conditioning plan, a change in transplant dates changes the palifermin dates too. If heparin is used to keep the IV line open, nurses rinse the line with saline before and after each dose.
Skin reactions are the most common effects: rash, redness, itching and swelling. In trials they began about six days after the first dose and usually lasted about five days. Serious rash was uncommon, affecting fewer than 1 in 100 people. Changes in the mouth are also common, including a thickened or discolored tongue, altered taste, and tingling or numbness around the lips and mouth. Some people have joint pain, general aches, fever or swelling of the body. Blood tests often show raised amylase and lipase, enzymes made by the salivary glands and pancreas. These rises were temporary, usually returned to normal by the day of the stem cell infusion, and did not need treatment. Reports since approval also include redness and swelling of the vaginal area, and hand-foot syndrome (painful redness of the palms and soles). So much happens at once during a transplant that it can be hard to tell which symptom comes from which treatment. A new rash, swelling or mouth change is worth mentioning to the transplant team so they can sort out the cause.
Palifermin stimulates epithelial cells, and many cancers other than blood cancers start in those cells and can carry the KGF receptor. In laboratory and animal studies at doses far higher than those used in people, it sped the growth of some human tumor cells. Whether this happens in people is not known, which is one reason palifermin is limited to blood cancers. In a study of people with multiple myeloma receiving high-dose melphalan, infections were more common in those given palifermin than in those given a placebo. In part of the same study, cataracts (clouding of the eye's lens) developed or worsened more often over the following year in the palifermin group, although the difference was not statistically certain. Palifermin is not recommended with that regimen. Based on animal studies, palifermin may harm a developing baby. Breastfeeding should stop during treatment and for at least two weeks after the last dose. Heparin, a blood thinner often used to keep IV lines open, binds to palifermin and increases the amount in the bloodstream, which is why the line is flushed between them. The other key interaction is with the chemotherapy itself, handled by the 24-hour spacing described under dosing.
Palifermin lowers the chance and length of severe mouth sores, but it does not prevent them for everyone. In the main trial of people receiving total body irradiation and high-dose chemotherapy before an autologous transplant, severe mucositis (ulcers bad enough that a person can manage only liquids, or cannot eat or drink at all) occurred in 63% of those given palifermin, compared with 98% of those given a placebo. The most severe level, where eating and drinking are not possible, fell from 62% to 20%. Overall, the typical number of days with severe mouth sores was 3 rather than 9, and people needed less opioid pain medicine. The realistic goal is fewer and shorter bad days, not a sore-free transplant. Palifermin is used alongside routine mouth care, pain control and nutrition support, not instead of them. The skin and tongue changes usually appear within the first week and fade within days. It is a single short course tied to one transplant, with nothing to continue afterward. Whether it is offered depends heavily on the conditioning regimen, so many people having a transplant will not be candidates.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share your experience taking Fibroblast Growth Factor 7, what you've noticed, or ask the community a question.